Nature Communications (Jul 2019)
A ZEB1/p53 signaling axis in stromal fibroblasts promotes mammary epithelial tumours
- Rong Fu,
- Chen-Feng Han,
- Ting Ni,
- Lei Di,
- Li-Juan Liu,
- Wen-Cong Lv,
- Yan-Ran Bi,
- Nan Jiang,
- Yin He,
- Hong-Mei Li,
- Shui Wang,
- Hui Xie,
- Bao-An Chen,
- Xiao-Sheng Wang,
- Stephen J. Weiss,
- Tao Lu,
- Qing-Long Guo,
- Zhao-Qiu Wu
Affiliations
- Rong Fu
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
- Chen-Feng Han
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
- Ting Ni
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
- Lei Di
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
- Li-Juan Liu
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
- Wen-Cong Lv
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
- Yan-Ran Bi
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
- Nan Jiang
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
- Yin He
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
- Hong-Mei Li
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
- Shui Wang
- Division of Breast Oncology, The First Affiliated Hospital, Nanjing Medical University
- Hui Xie
- Division of Breast Oncology, The First Affiliated Hospital, Nanjing Medical University
- Bao-An Chen
- Division of Hematology and Oncology, The Affiliated Zhong-Da Hospital, Southeast University
- Xiao-Sheng Wang
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
- Stephen J. Weiss
- The Life Sciences Institute, Rogel Cancer Center, Department of Internal Medicine, University of Michigan
- Tao Lu
- State Key Laboratory of Natural Medicines, Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University
- Qing-Long Guo
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
- Zhao-Qiu Wu
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University
- DOI
- https://doi.org/10.1038/s41467-019-11278-7
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 18
Abstract
In epithelial cells Zeb1 is involved in the epithelial to mesenchymal transition. In this study, the authors show in a mouse model of breast cancer, that Zeb1 expression in stromal cells is required for tumour formation and metastasis.
